

28 June 2024

## Section 708A Cleansing Statement

This notice is given by PharmAust Limited ACN 094 006 023 (**ASX: PAA**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) it has today issued a total of 49,112,814 fully paid ordinary shares (**Shares**) as follows:
  - (i) 47,961,498 Shares issued in relation to the Tranche 1 Placement to institutional and sophisticated investors at an issue price of \$0.19 (19 cents) per Share, as announced on Friday, 21 June 2024;
  - (ii) 625,000 Shares issued upon exercise of vested performance rights in accordance with the terms of the PharmAust Limited Employee Incentive Plan; and
  - (iii) 526,316 Shares issued at a deemed issue price of \$0.19 (19 cents) per Share to a corporate advisor as consideration for 12 months of investor relations services;
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (e) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

**-Ends-**

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

**For further information, please contact:**

**Dr Michael Thurn**  
**Managing Director**  
**[investorenquiries@pharmaust.com](mailto:investorenquiries@pharmaust.com)**

**P +61 (3) 9692 7222**  
**W [www.pharmaust.com](http://www.pharmaust.com)**

**Media:**  
**Catherine Strong**  
**Morrow Sodali**  
**[c.strong@morrrowsodali.com](mailto:c.strong@morrrowsodali.com)**  
**0406 759 268**

## About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in participants with ALS. PAA is in the planning stages for a registration adaptive Phase 2/3 STRIKE clinical study and anticipates commencing enrolment in H2 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.<sup>1</sup>

<sup>1</sup> <https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market>

## PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: <https://investorhub.pharmaust.com/>

